Navigation Links
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

Lung adenocarcinoma can display genetic mutations, including anaplastic lymphoma kinase (ALK) rearrangement and epidermal growth factor receptor (EGFR) mutations. Knowing whether the tumor displays either of these oncogenic mutations can be key to effective treatment, as different cancers respond to different agents.

Researchers at Seoul National University genotyped 95 Korean NSCLC patients into three groups: 43 (45%) had EGFR mutations; 15 (16%) showed ALK rearrangement; and 37 (39%) had wild type (WT) NSCLC.

All patients received 500 mg of pemetrexed every 21 days. Treatment was continued until disease progression warranted termination, unacceptable toxicity was found, or until the patient or physician decided to discontinue therapy. Tumor response was evaluated every two cycles, or earlier if there were clinical signs of progression.

Treatment with pemetrexed delayed time to progression (TTP) of the disease by a median 9.2 months in ALK-rearranged patients, compared with 1.4 months for patients with EGFR mutations and 2.9 months for wild type. Overall response rate was 46.7% for ALK-rearranged patients, compared with 4.7% for EGFR mutant and 16.2% for wild type. Disease control rate (DCR), including partial response plus stable disease, was 86.7% in ALK-rearranged patients, compared with 25.6% for EGFR mutant and 56.8% for wild type.

"Our study demonstrates that pemetrexed treatment produced significantly better outcomes in ALK-translocated NSCLC patients than in EGFR mutant or WT patients," researchers wrote. "DCRs, as well as overall response rates, were excellent in ALK-positive patients (86.7% of DCR and 46.7% of ORR). In addition, median TTP was nearly sixfold higher in ALK-positive NSCLC than in ALK-negative patients. ALK positivity alone was an independent predictor for the efficacy of pemetrexed treatment."

Although the study showed that ALK positivity could be a predictive biomarker for pemetrexed efficacy in patients with NSCLC, researchers cautioned that the larger size of the EGFR mutant group may have affected results, and that more studies were needed.


Contact: Rene McGaw
International Association for the Study of Lung Cancer

Related medicine news :

1. Key function of mutation in hereditary breast and ovarian cancer gene discovered
2. Trial of Cancer-Fighting Virus Shows Promise
3. Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study
4. UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug
5. Scripps Research scientists reveal how white blood cell promotes growth and spread of cancer
6. Research gives new hope to those with rare vascular cancer
7. MRI predicts survival in locally advanced rectal cancer
8. Research aims to starve breast cancer cells
9. Steve Jobs Faces Uphill Battle Against Cancer: Experts
10. Smoking soon after waking raises risk of lung and head and neck cancers
11. Plants could pave the way for new ovarian cancer treatments
Post Your Comments:
(Date:11/25/2015)... Chicago, IL (PRWEB) , ... November 25, 2015 , ... ... the assets of Tri Lite’s personal heating products business. Cozy Products explains ... low-wattage personal heaters that fit in well with the Cozy Products business model: to ...
(Date:11/25/2015)... ... 25, 2015 , ... SCOTTSDALE, AZ) - Today, Dr. ... both surgical and non-surgical treatments, announced the expansion of his private practice capabilities ... , Highly trained and nationally recognized for his natural approach, Dr. Todd ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw ... N.Y. “I thought there had to be a convenient and comfortable way to protect ... PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In doing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center for ... eating disorders as a result of the $20,000 raised at the center’s recent ... Run Golf Club in Eureka, will help individuals who otherwise might not seek ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the German Drugs ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/25/2015)... global healthcare industry is expected to grow at a rate ... has the highest projected growth at 12.7%, and ... is second with growth projected at 11.5%. ... 2013-2014, total government funded healthcare was nearly 68%. Federal government ... 2013-2014. In real terms, out of pocket expenditure increased by ...
Breaking Medicine Technology: